Philip Johnson

Philip Johnson is a Senior Level Drug Development Professional with extensive expertise in oncology pharmaceutical development and regulatory affairs, having worked with five leading companies including Ipsen, Lilly, Pfizer, Bayer, and Roche. Currently, they serve as the Senior Vice President and Head of Global Regulatory Affairs at Ipsen, providing strategic leadership and ensuring compliance with global regulations. Previously, Philip held significant roles, including Senior Vice President of Oncology Development at Lilly, where they oversaw a large team and facilitated the swift initiation of clinical studies, and Medicine Team Leader at Pfizer, leading efforts for the regulatory approval of key hematology-oncology drugs. Their educational background includes an MBA from Rutgers Business School and ongoing studies at Northwestern University's Kellogg School of Management.